Neogen Corporation Reports Q4 and Full-Year FY2026 Financial Results: Key Highlights, Price-Sensitive Information, and Guidance
Executive Summary
Neogen Corporation (NASDAQ: NEOG), a global leader in food and animal safety solutions, has released its financial results for the fourth quarter and full fiscal year 2026. The report provides a comprehensive view of operational performance, strategic initiatives, and forward-looking guidance, all of which contain information that could significantly impact shareholder value and the company’s share price.
Key Financial Highlights
- Q4 FY26 Revenue: \$225.3 million, representing a slight decrease of (0.1%) year-over-year.
- Core Growth: 4.3% for Q4 FY26, 1.9% for the full fiscal year.
- Full-Year FY26 Revenue: \$870.4 million, down (2.7%) from the previous year.
- Food Safety Segment:
- Q4 revenue grew 3.1%; Core Growth reached 5.8% (highest since FY2023).
- Animal Safety Segment:
- Q4 revenue was down (8.2%) year-over-year, but improved sequentially by 7% due to supply chain resolutions.
- Core Growth for Q4: 0.5%.
- Net Loss: \$11.3 million in Q4 FY26 (EPS: \$(0.05)), compared to a much larger loss of \$612.2 million (EPS: \$(2.82)) in the prior year.
- Adjusted Net Income: \$18.7 million in Q4 FY26 (Adjusted EPS: \$0.09).
- Adjusted EBITDA: \$45.4 million in Q4 FY26 (margin: 20.2%). Full-year Adjusted EBITDA: \$177.8 million.
- Cash Flow: Q4 operating cash flow was \$30.2 million; free cash flow was \$26.2 million.
- Gross Margin: Q4 FY26 gross margin improved to 47.8% from 41.2% in the prior year; Adjusted Gross Margin rose to 49.7% from 46.4%.
Strategic and Operational Developments
- Petrifilm® Manufacturing Transition:
- Company is on track to manufacture sellable Petrifilm® products at its Lansing site, beginning a multi-quarter transition in November 2026.
- First fully validated single kit unit (SKU) expected by end of August 2026.
- Go-to-Market Strategy:
- Company launching a new global solutions-based selling model, focusing sales resources on key markets, products, and customers.
- Unified solutions-based selling standards rolled out across all markets to enhance portfolio selling, deepen customer engagement, and leverage data analytics and technical support offerings.
- Genomics Division Divestiture:
- Management expects to close the sale of its Genomics business by end of the first half of FY27.
- FY27 guidance includes an estimate of \$92 million in revenue and \$13 million in Adjusted EBITDA from Genomics. Guidance will be updated post-sale.
FY2027 Guidance
- Full-Year FY27:
- Revenue: \$880–\$885 million
- Adjusted EBITDA: \$180–\$182 million
- Implied core growth: ~3% (excludes \$6 million Cleaners & Disinfectants revenue from FY26, assumes 1% currency headwind)
- Q1 FY27:
- Revenue: \$207–\$209 million
- Adjusted EBITDA: ~\$37 million
- Note: Q1 typically sees lower profitability due to seasonality and mix changes; management expects improvement through the year as investments and initiatives take effect.
Balance Sheet and Leverage
- As of May 31, 2026:
- Total assets: \$3.35 billion
- Total liabilities: \$1.25 billion
- Total stockholders’ equity: \$2.09 billion
- Total debt: \$793.7 million
- Cash and cash equivalents: \$185.5 million
- Net debt: \$608.2 million
- Free Cash Flow: \$31.9 million for FY26
- Net debt-to-Adjusted EBITDA: Calculated for leverage evaluation, but GAAP ratio not meaningful due to net loss.
Operational Risks & Forward-Looking Statements
- Risks:
- Integration of 3M Food Safety business
- Potential tax benefits from 3M transaction
- Supply chain, manufacturing disruptions, and dependency on key suppliers
- Internal controls, litigation, and legal proceedings
- Competition, product liability, and regulatory compliance
- Substantial indebtedness and deleveraging goals
- Potential asset impairments
- Climate change, ESG goals, and geopolitical risks
- Forward-Looking Guidance:
- Adjusted EBITDA and other non-GAAP metrics are not directly reconciled to GAAP net income due to forecasting complexity and material uncertainty of certain items (e.g., stock-based compensation, restructuring, impairment, legal/tax effects).
Shareholder and Price-Sensitive Information
- Strong improvements in gross margin and Adjusted EBITDA, despite revenue being slightly down, point to enhanced operational efficiency and pricing power.
- Completion and validation of Petrifilm® manufacturing transition and new sales model could drive future revenue growth and margin expansion.
- Upcoming divestiture of Genomics division is a significant portfolio action; guidance will change post-sale, potentially affecting valuation and share price.
- Cost-saving initiatives and transformation programs are already showing benefits in profitability measures.
- Management’s disciplined execution and focus on innovation and operational efficiency are positioned to enhance growth and profitability exiting FY27.
- Risks and uncertainties, especially regarding integration, supply chain, legal matters, and ESG, remain material for shareholders.
Conference Call and Webcast
Neogen will host a conference call at 8:00 a.m. Eastern Time. The webcast and presentation materials are available at neogen.com/investor-relations. A replay will be available post-call.
Contact Information
- Investor Contact: Scott Gleason (435) 395-0254 | [email protected]
- Media Contact: Lauren White (202) 320-8677 | [email protected]
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are based on Neogen management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review the company’s filings and disclosures for a full understanding of risks and financial performance. The author assumes no responsibility for investment decisions based on this summary.
